Chris Schaumburg

Dr. Chris Schaumburg is an immunologist and business development leader with 15 years of cross-functional experience in scientific research, pharmaceutical drug discovery and development, and business development and strategy. Chris currently serves as Vice President of pipeline strategy at Prometheus Biosciences (Nasdaq: RXDX), a biopharma company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic product candidates to treat immune-mediated diseases. Chris previously served as Vice President and head of business development at Urovant Sciences, Inc (formerly Nasdaq: UROV prior to acquisition by Sumitomo Dainippon). Chris began his career in the lab, where his research focused on inflammation and the development and progression of autoimmune disease. Among his prior roles, Chris was co-director of the Inflammation Research Program at Allergan, Inc. where he focused on drug discovery and development and strategy in the company’s largest therapeutic area. Chris holds a PhD from the University of California, Irvine and an MBA from UCLA Anderson School of Management.